MammaPrint 70-gene signature: another milestone in personalized medical care for breast cancer patients.

@article{Slodkowska2009MammaPrint7S,
  title={MammaPrint 70-gene signature: another milestone in personalized medical care for breast cancer patients.},
  author={Elzbieta A Slodkowska and Jeffrey S. Ross},
  journal={Expert review of molecular diagnostics},
  year={2009},
  volume={9 5},
  pages={417-22}
}
The MammaPrint assay (Agendia BV, The Netherlands) is the first fully commercialized microarray-based multigene assay designed to individualize treatment for patients with breast cancer. MammaPrint, the first assay to be cleared at the 510(k) level by the US FDA's new in vitro diagnostic multivariate index assay classification, is offered as a prognostic test for women under the age of 61 years with either estrogen receptor-positive or -negative, lymph node-negative breast cancer. Unlike the… CONTINUE READING